Given the success of the gene therapy treatment of biallelic RPE65 retinopathies with Luxturna [16], an AAV-based therapy, it is interesting to speculate whether the therapy might have any utility for monoallelic dominant RPE65 cases. Here, RPE65 is linked to retinal disorder.